GLPG Quote, Financials, Valuation and Earnings

MDxHealth SA has a net margin of 33.52% compared to Galapagos NV's net margin of -27.65%. Galapagos NV's return on equity of 2.55% beat MDxHealth SA's return on equity of -395.93%.

Galapagos NV has a consensus price target of $31.36, signalling upside risk potential of 31.02%. On the other hand MDxHealth SA has an analysts' consensus of $6.0400 which suggests that it could grow by 277.5%. Given that MDxHealth SA has higher upside potential than Galapagos NV, analysts believe MDxHealth SA is more attractive than Galapagos NV.

Galapagos NV has a beta of 0.159, which suggesting that the stock is 84.055% less volatile than S&P 500. In comparison MDxHealth SA has a beta of -458,274.035, suggesting its less volatile than the S&P 500 by 45827503.54%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MDxHealth SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. MDxHealth SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $80.5M, which are larger than MDxHealth SA quarterly revenues of $24.7M. Galapagos NV's net income of $27M is higher than MDxHealth SA's net income of -$6.8M. Notably, Galapagos NV's price-to-earnings ratio is 19.95x while MDxHealth SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.28x versus 0.67x for MDxHealth SA. Usually stocks with elevated PS ratios are considered overvalued.

Nyxoah SA has a net margin of 33.52% compared to Galapagos NV's net margin of -1357.8%. Galapagos NV's return on equity of 2.55% beat Nyxoah SA's return on equity of -56.62%.

Galapagos NV has a consensus price target of $31.36, signalling upside risk potential of 31.02%. On the other hand Nyxoah SA has an analysts' consensus of $15.08 which suggests that it could grow by 152.13%. Given that Nyxoah SA has higher upside potential than Galapagos NV, analysts believe Nyxoah SA is more attractive than Galapagos NV.

Galapagos NV has a beta of 0.159, which suggesting that the stock is 84.055% less volatile than S&P 500. In comparison Nyxoah SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nyxoah SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Nyxoah SA pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $80.5M, which are larger than Nyxoah SA quarterly revenues of $1.3M. Galapagos NV's net income of $27M is higher than Nyxoah SA's net income of -$18.3M. Notably, Galapagos NV's price-to-earnings ratio is 19.95x while Nyxoah SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.28x versus 39.97x for Nyxoah SA. Usually stocks with elevated PS ratios are considered overvalued.

Remedent has a net margin of 33.52% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of 2.55% beat Remedent's return on equity of --.

Galapagos NV has a consensus price target of $31.36, signalling upside risk potential of 31.02%. On the other hand Remedent has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than Remedent, analysts believe Galapagos NV is more attractive than Remedent.

Galapagos NV has a beta of 0.159, which suggesting that the stock is 84.055% less volatile than S&P 500. In comparison Remedent has a beta of -0.150, suggesting its less volatile than the S&P 500 by 115.037%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Remedent offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galapagos NV pays -- of its earnings as a dividend. Remedent pays out -- of its earnings as a dividend.

Galapagos NV quarterly revenues are $80.5M, which are larger than Remedent quarterly revenues of --. Galapagos NV's net income of $27M is higher than Remedent's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 19.95x while Remedent's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.28x versus 0.48x for Remedent. Usually stocks with elevated PS ratios are considered overvalued.

UCB SA has a net margin of 33.52% compared to Galapagos NV's net margin of --. Galapagos NV's return on equity of 2.55% beat UCB SA's return on equity of 11.39%.

Galapagos NV has a consensus price target of $31.36, signalling upside risk potential of 31.02%. On the other hand UCB SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Galapagos NV has higher upside potential than UCB SA, analysts believe Galapagos NV is more attractive than UCB SA.

Galapagos NV has a beta of 0.159, which suggesting that the stock is 84.055% less volatile than S&P 500. In comparison UCB SA has a beta of 0.758, suggesting its less volatile than the S&P 500 by 24.243%.

Galapagos NV has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UCB SA offers a yield of 0.91% to investors and pays a quarterly dividend of $0.72 per share. Galapagos NV pays -- of its earnings as a dividend. UCB SA pays out 24.32% of its earnings as a dividend. UCB SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Galapagos NV quarterly revenues are $80.5M, which are larger than UCB SA quarterly revenues of --. Galapagos NV's net income of $27M is higher than UCB SA's net income of --. Notably, Galapagos NV's price-to-earnings ratio is 19.95x while UCB SA's PE ratio is 27.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galapagos NV is 5.28x versus 4.73x for UCB SA. Usually stocks with elevated PS ratios are considered overvalued.